Document Classification

Section Type: RESULTS

Text: In the per-protocol population (n = 320), WBRT nonsignificantly prolonged progression-free survival (PFS) (median 18. 2 vs 11. 9 months, hazard ratio [HR] 0. 83 [95 % confidence interval (CI) 0. 65-1. 06], p = 0. 14) and significantly PFS from last HDMTX (25. 5 vs 12. 0 months, HR 0. 65 [95 % CI 0. 5-0. 83], p = 0. 001), but without OS prolongation (35. 6 vs 37. 1 months, HR 1. 03 [95 % CI 0. 79-1. 35], p = 0. 82).